Universal building blocks for antigen presentation to uncover the flavivirus-directed antibody response
The FLAVIR project aims to develop a structural proteomics toolkit using mass spectrometry and electron microscopy to enhance understanding of neutralizing antibody responses against flaviviruses for vaccine development.
Projectdetails
Introduction
Flaviviruses are a tremendous burden on global public health. The genus consists of yellow fever virus, dengue virus, and zika virus amongst others. These viruses threaten more than half the global human population and are spreading into new territories. The recent zika virus pandemic stresses the need for a suitable protein engineering toolkit to enable swift development of emerging flavivirus antigens for structural studies, serology, and vaccine development.
Current Challenges
Moreover, the structural determinants of a neutralizing polyclonal antibody response are currently not well understood, in large part due to a lack of suitable methods to address the complex interactions of multiple antibodies directed against a heterogeneous, glycosylated viral antigen.
Project Overview
With FLAVIR, I will use my unique expertise in both mass spectrometry and electron microscopy to develop a comprehensive structural proteomics toolkit for in-depth profiling of the neutralizing antibody response against flaviviruses.
Methodology
Using a combination of novel mass spectrometry-based antibody sequencing techniques, glycoproteomics profiling, and electron microscopy, we will uncover how the polyclonal antibody response against flaviviruses is directed by key structural determinants of the Envelope glycoprotein that is displayed on the surface of infectious virions.
Development Strategies
We will develop new strategies to:
- Produce prefusion stabilized E-dimers.
- Ultimately reconstruct full icosahedral flavivirus-like particles from soluble components.
The outlined strategies will be tested and streamlined for broad applicability across the flaviviruses so that they can be swiftly adapted for emerging species and strains.
Characterization Techniques
We will characterize our designs with state-of-the-art mass spectrometry methods (native MS, mass photometry, HDX-MS) and electron microscopy.
Antigen Optimization
We will use these optimized antigens to uncover the role of antigen glycosylation in antibody binding, profile the serum antibody repertoire directed against the E-antigen, and map out...
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.687.500 |
Totale projectbegroting | € 1.687.500 |
Tijdlijn
Startdatum | 1-8-2023 |
Einddatum | 31-7-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT UTRECHTpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Structure and Function-based Design of Vaccine Antigens and Antiviral ImmunotherapiesThis project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses. | ERC Starting... | € 1.499.525 | 2025 | Details |
Molecular dissection of viral genomes for future antiviral treatmentsThis project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections. | ERC Advanced... | € 2.420.301 | 2023 | Details |
Multivalent Supramolecular Nanosystems as Dynamic Virus BlockersSupraVir aims to develop self-adaptive supramolecular assemblies that mimic host cell receptors to create universal virus blockers effective against diverse and rapidly mutating viruses. | ERC Advanced... | € 2.849.138 | 2022 | Details |
PROposing Action to ConTrol and Impede betacoronaVirus EmergenciesDevelop vaccines and monoclonal antibodies targeting subdominant epitopes of SARS-CoV-2 to ensure broad protection against current and future variants, enhancing global pandemic preparedness. | ERC Advanced... | € 2.498.750 | 2023 | Details |
Mosquito-virus matchmaking: Elucidating the biological basis of compatibility between viruses and mosquitoesThis project aims to utilize single-cell technology and gene editing to understand and manipulate the compatibility between viruses and mosquito vectors, enhancing disease control strategies. | ERC Starting... | € 1.500.000 | 2023 | Details |
Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies
This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.
Molecular dissection of viral genomes for future antiviral treatments
This project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections.
Multivalent Supramolecular Nanosystems as Dynamic Virus Blockers
SupraVir aims to develop self-adaptive supramolecular assemblies that mimic host cell receptors to create universal virus blockers effective against diverse and rapidly mutating viruses.
PROposing Action to ConTrol and Impede betacoronaVirus Emergencies
Develop vaccines and monoclonal antibodies targeting subdominant epitopes of SARS-CoV-2 to ensure broad protection against current and future variants, enhancing global pandemic preparedness.
Mosquito-virus matchmaking: Elucidating the biological basis of compatibility between viruses and mosquitoes
This project aims to utilize single-cell technology and gene editing to understand and manipulate the compatibility between viruses and mosquito vectors, enhancing disease control strategies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and ZikaATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Protini pan-Corona antiviralsProtinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden. | Mkb-innovati... | € 20.000 | 2020 | Details |
The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika
ATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization.
Protini pan-Corona antivirals
Protinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden.